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ABSTRACT
Objective: Little is known about the practice of
predicting community-based care effectiveness of
patients affected by schizophrenic disorders. We
assessed predictors of treatment failure in a large
sample of young people affected by schizophrenia.
Methods: A cohort of 556 patients aged 18–35 years
who were originally diagnosed with schizophrenia
during 2005–2009 in a Mental Health Service (MHS) of
the Italian Lombardy Region was identified. Intensity of
mental healthcare received during the first year after
index visit (exposure) was measured by patients’
regularity in MHS attendance and the length of time
covered with antipsychotic drug therapy. Patients were
followed from index visit until 2012 for identifying
hospital admission for mental disorder (outcome).
A proportional hazards model was fitted to estimate the
HR and 95% CIs for the exposure-outcome
association, after adjusting for several covariates.
A set of sensitivity analyses were performed in order to
account for sources of systematic uncertainty.
Results: During follow-up, 144 cohort members
experienced the outcome. Compared with patients on
low coverage with antipsychotic drugs (≤4 months),
those on intermediate (5–8 months) and high
(≥9 months) coverage, had HRs (95% CI) of 0.94
(0.64 to 1.40) and 0.69 (0.48 to 0.98), respectively.
There was no evidence that regular attendance at the
MHS affected the outcome.
Conclusions: Patients in the early phase of
schizophrenia and their families should be cautioned
about the possible consequences of poor antipsychotic
adherence. Physicians and decision makers should
increase their contribution towards improving mental
healthcare.
INTRODUCTION
The ﬁfth edition of the Diagnostic and
Statistical Manual of Mental Disorders
deﬁnes schizophrenia as a syndrome charac-
terised by a long duration and high relapse
rate, with abnormalities in one or more of
the following ﬁve domains: delusions, halluci-
nations, disorganised thinking (speech),
grossly disorganised or abnormal motor
behaviour, including catatonia and negative
symptoms, and sometimes mood problems.1
The onset of symptoms typically occurs in
adolescence and young adulthood, with a
worldwide estimate of lifetime prevalence
and incidence of 1.4–4.6 and 0.16–0.42
per 1000 persons annually, respectively.2 3
A recent systematic review indicated that
patients diagnosed with this disorder have a
shorter lifespan than the average general
population. Furthermore, they have an
increased risk of suicide and physical impair-
ment (eg, limited exercise, poor diet and
obesity), and reduced access to medical treat-
ment and healthcare services.4
Antipsychotic medications have been
recommended as the mainstream of medical
treatment for nearly all patients with
Strengths and limitations of this study
▪ The investigation is based on data from a large
unselected population that were available since
practically all citizens in Italy are covered by a
cost-free healthcare system.
▪ Our data reflect routine clinical practice and are
not affected by selective participation and recall
bias.
▪ Patients were identified from the point of the
initial visit with the mental health service in
which diagnosis of schizophrenia was made, and
the complete sequence of public or accredited
healthcare facilities, including mental healthcare
and other services, was known.
▪ Evaluation of antipsychotic drug coverage was
based on pharmacy-dispensing information. This
method assumes that the proportion of days
covered by a prescription corresponds to the
proportion of days of medication use.
▪ Notwithstanding the large sample size, our study
was not sufficiently powered to investigate the
effect of relatively rare exposures.
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schizophrenia, to provide them with a safe and thera-
peutic environment, and effective symptom control.5 In
the last few decades, different approaches to psycho-
social interventions (eg, psychotherapy, family therapy,
psychoeducation and cognitive–behavioural therapy)
have shown to be able to bear positive patient outcomes,
admitted that they are used as an adjunct to antipsycho-
tics.6–13 Although their comparative efﬁcacy has been
increasingly evaluated in various clinical trials,7 9 11 12 it
should be emphasised that patients enrolled in these
trials were likely quite motivated, as they were consent-
ing to intense monitoring in a structured research pro-
gramme, and likely adhered to, or were controlled for
adherence, with clinical recommendations.
Unfortunately, however, how these intervention pro-
grammes perform in psychiatrically ill patients treated in
real-world, naturalistic settings, is little known.
Mental health services (MHS) play a central role in
the treatment of people with schizophrenic disorders, as
they act both as direct providers of care and as suppor-
ters of primary care practitioners.14 In accordance with
the Italian model of MHS, as well as with that of most
high-income countries, a complex network of different
types of community mental health teams, and a range of
treatment, rehabilitation, employment and residential
care facilities, currently operate in the community.15 To
date, however, little is known about the practice and
patient characteristics that predict effectiveness of
community-based care patients affected by schizophrenic
disorders. This paper is designed to address this need.
Our purpose is to assess predictors of treatment failure
in a large and unselected sample of young people
affected by schizophrenia.
METHODS
Departments of mental health in Lombardy
Lombardy, the largest and the most afﬂuent region in
Italy with, in 2009, a population of about 9 700 000, lies
in the northernmost part of the country. In Lombardy,
the public Department of Mental Health (DMH) pro-
vides mental healthcare through a network of commu-
nity services, ranging from acute emergency treatment
to long-term rehabilitation; it therefore includes one or
more of all the following facilities: community Mental
Health Centres, General Hospital Psychiatric Wards
(GHPW), Day Care Centres, community Residential
Facilities (RF). The public DMH is an administrative,
ﬁnancial and organisational entity, and is fully respon-
sible for the network of community mental health facil-
ities in the catchment area, including GHPWs and
public RFs. It has full governance of all the available
facilities in the Department, and also authorises and
controls the admission of DMH patients to private,
licensed facilities, such as private RFs.16
Healthcare utilisation databases of Lombardy
In Italy, the population is covered by the National
Health Service (NHS), and in Lombardy, its
management has been associated with an automated
system of databases since 1997, which collect a variety of
information concerning services provided to beneﬁciar-
ies of NHS. Information includes data on patients
attending public DMH, for example, demographics,
International Classiﬁcation of Diseases, 10th edition
(ICD-10) diagnoses, treatments such as outpatient and
home visits, day treatment attendance and admittance to
RFs. Besides the speciﬁc system for monitoring the use
of MHS, other automated systems for monitoring health-
care utilisation include: databases on diagnosis at dis-
charge from public or private hospitals; outpatient drug
prescriptions reimbursed by the NHS: drug prescriptions
administered directly in the outpatient setting and day
hospital; and outpatient services, such as visits and diag-
nostic tests, respectively, performed in specialist ambula-
tories and laboratories accredited by the NHS. For each
patient, we linked the above databases via a single identi-
ﬁcation code. In order to preserve privacy, each identiﬁ-
cation code was automatically converted to an
anonymous code. The inverse process was prevented by
deletion of the conversion table.
Through this record linkage process we were able to
mark out the complete care pathway of all the citizens of
Lombardy who are beneﬁciaries of NHS, comprising
practically all residents in the region, through a long
period of observation. This offers the opportunity to
design investigations including very large unselected
populations, and to generate real-world evidence on
several ﬁelds of healthcare, including mental health.17 18
Cohort selection and follow-up
The target population consisted of all beneﬁciaries of
the NHS resident in Lombardy and aged 18–35 years.
According to the 2011 Italian Census, this population
amounted to 1 893 313 individuals. Of these, we identi-
ﬁed patients who, during 1 January 2005 to 31
December 2009, had at least one contact with an MHS
accredited by the NHS, and who received, on that occa-
sion, the diagnosis of schizophrenia spectrum disorder
(ICD-10 codes 2X.XX). The date of the ﬁrst visit during
the considered period was recorded as the index visit.
With the aim of favouring the inclusion of only newly
treated individuals, patients who within 2 years prior to
the index visit experienced at least one hospital admis-
sion for mental disorder (ICD-9 290-319), had at least
one contact with an MHS, or who simply received a pre-
scription for an antipsychotic agent, were excluded.
Patients who, during the ﬁrst year after index visit, did
not receive antipsychotic medicaments, were also
excluded, based on the assumption that in these
patients, continuous drug treatment might not have
been indicated. Finally, patients who did not reach at
least 1 year of follow-up were excluded, to ensure at least
1 year of potential exposure to the care of interest. The
remaining patients represented the study cohort.
Each member of the cohort accumulated person-years
of follow-up from the index visit until the earliest among
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the dates of outcome onset (ie, hospital admission for
mental disorder) or censoring (ie, death from any
cause, emigration, or 31 December 2012).
Characterising cohort members
For each cohort member, data included selected tracts
detected at the index visit, such as gender, age, social
tracts and physical comorbidities. The latter were mea-
sured by means of the Charlson comorbidity index
score,19 which was calculated via the diagnostic informa-
tion available from inpatient charts in the 2 years prior,
and 1 year after, the index visit; patients were categorised
as either having or not having chronic comorbidities.
Finally, cotreatments with antidepressive and mood stabi-
lisers during the ﬁrst year after the index visit were
considered.
Measuring mental healthcare
All contacts with an MHS experienced by the cohort
members during the ﬁrst year after the index visit were
identiﬁed. Attendance was considered regular if the
time span between two consecutive visits was 60 days or
shorter, or as discontinued, otherwise. Patients were clas-
siﬁed into two mutually exclusive categories of those
who had regular attendance with the MHS (ie, if they
did not experience any episode of discontinuation
through the ﬁrst year after the index visit), or were dis-
continuers otherwise.
Patients were, furthermore, classiﬁed according to if
they received at least three individual, familiar or group
sessions of psychotherapy, family psychoeducational
activities or other supports (eg, social, expressive, prac-
tical–manual, physical activities, and support in inde-
pendent living and in employment).
Data were also regarded in relation to the profes-
sionals who supplied care, distinguishing between
patients who were seen only by mental health staff (psy-
chiatrists and psychologists), or also by other profes-
sionals (educators, social workers, etc).
Coverage with antipsychotic drug therapy was mea-
sured by means of the cumulative number of days
during which the medication was available. Patients
were, accordingly, categorised as having at least
4 months, from 5 to 8 months, and more than 9 months
of drug coverage.
Data analysis
The Kaplan-Meier estimator of the cumulative propor-
tion of patients experiencing the outcome was built for
the entire cohort, as well as according to selected sub-
groups. The log-rank test was used to rate between
group differences. The Cox proportional hazard regres-
sion model was ﬁtted to estimate the HR and its 95% CI
for the association between the above listed covariates,
and time of outcome onset. Trends in HRs were tested,
when feasible, according to the statistical signiﬁcance of
the regression coefﬁcient of the recoded variables
obtained by scoring the corresponding categories.
Sensitivity analyses
Because of the arbitrariness of taking a 60-day time span
to distinguish regular and discontinuing attendance,
and to account for at least three psychotherapy sessions
to identify patients treated, data were reanalysed accord-
ing to different criteria, such as 30-day and 90-day time
spans, and one or two sessions of psychotherapy.
The robustness of our ﬁndings with regard to poten-
tial bias introduced by unmeasured confounders was
investigated by using the rule-out approach described by
Schneeweiss.20 Let E be the exposure of interest (eg, the
regular attendance to the MHS contrasted with discon-
tinuation), O the outcome (ie, hospital admission for
mental disorder) and C a hypothetical unmeasured con-
founder (eg, severity of schizophrenia at diagnosis). In
applying the rule-out method, we allowed C: (1) to be
present in the study population with a prevalence of
50% (eg, one half of included patients had symptoms of
severe schizophrenia at index visit); (2) to be associated
with O with risk ratio varying from 1 to 10 (ie, severe
schizophrenics may experience the outcome up to
10-fold more than patients with less severe symptoms)
and (3) to be associated with E with OR varying from
1 to 10 (ie, severe schizophrenics may regularly attend
the service up to 10-fold more than others). In its ori-
ginal formulation, the rule-out approach aims to detect
the extension of confounding required to fully account
for the observed exposure–outcome association, so as to
drag the observed point estimate towards that expected
under the null hypothesis. In our application, we
extended the use of the rule-out approach in the situa-
tions where the observed association did not reach statis-
tical signiﬁcance, and the interest was to detect the
extension of confounding required to make statistically
signiﬁcant the exposure–outcome association. With this
aim, we conducted the analysis for the value of the
observed higher 95% conﬁdence limit to determine
the constellations in which the 95% CI would not cross
the expected value under the null hypothesis.
RESULTS
The distribution of the exclusion criteria is shown in
ﬁgure 1. The 556 patients who met inclusion criteria
accumulated 2619 person-years of observation, with an
average per-patient follow-up of about 4.7 years. During
this period, 144 patients belonging to the cohort
members experienced the outcome.
Table 1 provides some characteristics of the included
cohort members. At the index visit, almost one half of
the patients were aged 30–35 years, and 68% of them
were men. Most patients had poor education, were
never married and/or lived as a family and almost 60%
were unemployed. Only two patients showed at least one
sign of chronic comorbidity. More than one half of the
patients were co-treated with antidepressive agents, and
one in seven patients was co-treated with mood stabiliser
agents. Among the considered covariates were evidence
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of increased outcome risk issued for patients with poor
education, currently unemployed, and those who did
not receive antidepressive agents.
As far as mental healthcare provided to cohort
members during the ﬁrst year after index visit is con-
cerned, table 2 shows that, although only one in ﬁve
patients had good coverage with antipsychotic drug
therapy, signiﬁcant reduction of the outcome risk was
observed for these patients. The inverse coverage–
outcome relationship is depicted in ﬁgure 2. In particu-
lar, the cumulative proportion of patients experiencing
the outcome decreased from 34% to 32% and 23% for
patients with low, intermediate and high drug coverage,
respectively.
Table 2 shows that most patients received interventions
delivered by professionals other than psychiatrists and
psychologists; 12% received at least three sessions of psy-
chotherapy, and one-quarter of patients had regular
MHS attendance without any episode of discontinuation
during the ﬁrst year after the index visit. There was no
evidence that type of treatment, role of caregivers, or
regular attendance with MHS, affected the outcome risk.
As expected, the proportion of regularly attending
patients, as well as that of adequately treated patients,
decreases as less permissive criteria were adopted.
Figure 3 shows that regulars accounted for only 5% by
allowing 30 days between two consecutive visits, while
42% of patients had ‘regular’ contacts at least every
90 days. Among the 124 patients who received a ﬁrst
psychotherapy session, only 66 (53%) reached at least
three sessions. It should be noted, however, that the
lack of evidence of a protective effect of care was pro-
vided by territorial services even by varying the classiﬁ-
cation criteria.
The results of the residual confounding analysis
obtained by means of the rule-out approach are pre-
sented in ﬁgure 4. If we assume that patients exposed to
the unmeasured confounder have a fourfold increased
outcome risk than those unexposed (ie, severe schizo-
phrenics experience the outcome fourfold more than
others), then patients exposed to the confounder would
increase their exposure of 5.3-fold or more (ie, severe
schizophrenics would regularly attend the service with
odds more than ﬁvefold higher than others) to inﬂu-
ence the effect of regular attendance to be signiﬁcantly
protective on the outcome risk. On the other hand, if
we assume that patients exposed to the confounder have
even higher outcome risk (eg, severe schizophrenics
Figure 1 Flow chart of inclusion
and exclusion criteria. DMH,
Department of Mental Health;
Lombardy Region, Italy, 2005–
2012.
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experience the outcome 10-fold more than others),
then a lower discrepancy of the exposure of interest is
required to admit protection (ie, severe schizophrenics
would regularly attend the service more than threefold
higher than others).
DISCUSSION
Our population-based cohort study shows that mental
healthcare provided to young schizophrenic patients is
frequently abandoned and/or is not adequately followed
up since the ﬁrst year after diagnosis. Consistently, and
with an impressive amount of literature,21 this was
observed with regard to antipsychotic drug therapy,
since only one in ﬁve patients had good coverage with
antipsychotic drug therapy. Furthermore, only 1 patient
in 20 had monthly attendance of a territorial MHS, and
58% of schizophrenics had attended the service less
than once every 3 months.
An important ﬁnding of our study is that, in the real-
world setting, the longer the coverage with antipsychotic
drug therapy during the ﬁrst year after diagnosis of
schizophrenia, the greater the reduction in the risk of
long-term hospital admission for mental disorder.
Thus, our ﬁndings suggest that treatment with antipsy-
chotics may favourably affect the risk of hospitalisation,
a conclusion that expands, to a large unselected popu-
lation, the conclusions of several observational
studies,22–25 and a recent systematic review of rando-
mised clinical trials.26 The poor compliance with drug
therapy in everyday clinical practice, together with the
observed strength of the association between drug
coverage and outcome, given a 21% attributable frac-
tion, which is more than one-ﬁfth of outcome currently
occurring among schizophrenics who received anti-
psychotic drug therapy at baseline, may be prevented if
all those patients had good coverage with therapy.
Hence, among the investigated factors, poor coverage
Table 1 Selected tracts of the 556 included patients with diagnosis of schizophrenia and their relationship with the long-term
risk of hospital admission for mental disorders (Lombardy Region, Italy, 2005–2012)
N (%)
Rough HR*
(95% CI)
Adjusted HR*
(95% CI)
Demographics†
Male gender 80 (68) 1.05 (0.74 to 1.49) 1.04 (0.72 to 1.49)
Age (years)
18–23 144 (26) 1.00 (reference) 1.00 (reference)
24–29 160 (29) 0.72 (0.46 to 1.11) 0.75 (0.46 to 1.17)
30–35 252 (45) 0.83 (0.56 to 1.22) 0.89 (0.60 to 1.33)
ptrend‡ 0.269 0.343
Social tracts†
Education (years)
≤8 323 (58) 1.00 (reference) 1.00 (reference)
9–14 195 (35) 0.72 (0.05 to 1.03) 0.80 (0.55 to 1.16)
>14 38 (7) 0.49 (0.22 to 1.12) 0.51 (0.26 to 0.99)
ptrend§ 0.020 0.046
Marital status
Married 94 (17) 1.00 (reference) 1.00 (reference)
Never married 462 (83) 0.95 (0.62 to 1.46) 0.88 (0.55 to 1.42)
Living arrangements
Alone 34 (6) 1.00 (reference) 1.00 (reference)
Family 513 (92) 1.04 (0.51 to 2.12) 0.70 (0.49 to 1.00)
Community 9 (2)
Employment
Currently unemployed 324 (58) 1.00 (reference) 1.00 (reference)
Currently employed 232 (42) 0.65 (0.46 to 0.91) 0.74 (0.55 to 0.99)
Cotreatments and comorbidities
Physical comorbidities¶
None 554 (99) – –
One or more 2 (1) – –
Cotreatments‡
Antidepressive 274 (49) 0.67 (0.48 to 0.93) 0.66 (0.47 to 0.93)
Mood stabilisers 84 (15) 1.41 (0.93 to 2.14) 1.51 (0.98 to 2.33)
Estimates were rough and mutually adjusted for covariates listed in tables 1 and 2.
*HR (and 95% CI) for the risk of hospital admission for mental disorders, according to a Cox proportional hazard model.
†At baseline (index visit).
‡During the first year after index visit.
§p Value for the trend in the risk of outcome as the category of the corresponding variable increases.
¶According to diagnostic information available from inpatient charts in the 2 years prior and 1 year after the index visit.
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with antipsychotic drugs appears the more important
predictor.
Another important ﬁnding of our study is that, unex-
pectedly, regular attendance of a territorial MHS for
receiving psychotherapy, psychoeducational activities,
social supports and multidisciplinary care, did not show
evidence of exerting a protective effect on the risk of hos-
pitalisation in our setting. Although it is difﬁcult to draw
consistent conclusions from the existing literature on the
efﬁcacy of psychological interventions in the therapy of
schizophrenic patients, there is, however, sound evidence
for the efﬁcacy of speciﬁc psychological approaches, that
is, social skills training, cognitive remediation, psychoedu-
cational interventions with families and relatives, and cog-
nitive behavioural therapy of psychotic symptoms.11 This
suggested their implementation into routine care accord-
ing to several national guidelines.27 However, the main
open question remains the generalisability of randomised
control trial ﬁndings to routine care. Our study suggests
that the gap between what is known from clinical efﬁcacy
research and the systematic community translation of
mental healthcare programmes is still dramatically wide,
at least in the investigated setting.
Other ﬁndings of our study deserve to be mentioned.
First, we observed that almost one half of the included
patients were aged 30–35 years, that is, they were much
older than expected for a group experiencing a ﬁrst
episode of psychosis. This reveals that accessibility to
public MHS should be improved for intercepting early
onset of schizophrenic disorders. Second, among the
considered social tracts, low level of education and
unemployment were independent predictors of long-
term risk of hospital admission for mental disorders,
possibly due to the treatment delay, and then to the
greater severity of illness at presentation, among people
with low socioeconomic status.28 Finally, we observed
that almost one half of the included patients co-utilised
antidepressants, and that these patients were at lower
risk of long-term mental disorder hospitalisation. This
ﬁnding conﬁrms recent evidence that antidepressants
along with antipsychotics are more effective in treating
the negative symptoms of schizophrenia than antipsycho-
tics alone.29
The present study is unique in several respects. One,
the investigation is based on data from a large unse-
lected population, which was made possible since prac-
tically all citizens in Italy are covered by a cost-free
healthcare system. Two, our data reﬂect routine clinical
practice and are not affected by selective participation
and recall bias. Three, patients were identiﬁed from the
point of the initial visit with the MHS in which diagnosis
of schizophrenia was made, and the complete sequence
of public or accredited healthcare facilities, including
mental healthcare and other services, was known. Four,
accurate data are guaranteed from healthcare utilisation
databases of Lombardy, as documented by several
quality checks.30–32 Finally, a number of sensitivity ana-
lyses conﬁrmed the robustness of our ﬁndings.
Our study may be limited by some issues. One, informa-
tion about private mental health outpatient facilities is not
available from our healthcare utilisation databases system.
This involves the following systematic errors: (1) we select-
ively included patients who had at least a visit with a public
structure; (2) we cannot exclude that some of the included
patients already had visits with private structures, so that,
despite our best efforts, some prevalent cases were select-
ively included and (3) the pathway of care that we were able
to trace lacks for a part of clinical supplies. It should be
emphasised, however, that the access to private facilities
does not affect our ability to search out drug dispensations.
In fact, according to the Italian health system organisation,
free-of-charge drug prescriptions are, however, ensured
(and then recorded in the healthcare utilisation database),
even when they have been prescribed by a private physician.
This can be explained because, among the investigated
healthcare cases, only drug therapy showed evidence of
effectiveness.
Two, evaluation of antipsychotic drug coverage was
based on pharmacy-dispensing information. This
method assumes that the proportion of days covered by
a prescription corresponds to the proportion of days of
medication use. Although data on dispensing history
have shown to be consistent with other adherence mea-
sures, drug serum levels and clinical drug effects,33 it is
likely that in a number of patients the prescribed drugs
are not consumed. This implies that the use of medica-
tion dispensing as a measure of coverage remains a
source of uncertainty of our estimates. It should be men-
tioned, however, that this source of misclassiﬁcation
likely leads to an underestimation of the strength of
adherence-outcome association.34
Figure 2 Cumulative proportion of patients experiencing
hospitalisation for mental disorders, according to their
coverage with antipsychotic drug therapy during the first year
since index visit. Lombardy Region, Italy, 2005–2012.
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Three, whether the observed ﬁndings are due to our
inability to fully account for regular treatment to those
patients at higher risk of clinical failure, is a relevant
question in interpreting our ﬁndings. For example, it is
likely that patients with severe schizophrenia at baseline
are submitted to greater psychiatric attention than those
with less severe symptoms, that is, more regular visits,
greater care for therapeutic plan and longer drug cover-
age. Our study addressed confounding by means of the
following insights. First, conventional adjustments for a
number of available demographic, therapeutic and clin-
ical characteristics, such as age, gender, social features
and co-treatments, where most of them that may be con-
sidered proxies of disease severity, were performed.
Second, we attempted to include patients at their ﬁrst
clinical manifestation of the disease. This was accom-
plished by excluding patients aged 35 years or over who
had already received a diagnosis of schizophrenia, and
those who had contacts with a department of mental
health, experienced hospitalisations for mental dis-
order, or who had simply received antipsychotic drug
dispensations. The exclusion of prevalent cases, as well
as of prevalent drug users, is crucial for healthcare
research, since the alternative consists in selectively
including those patients who survived their disease
status.35 Third, we excluded schizophrenics who did
not receive antipsychotic drug dispensations during the
ﬁrst year after the index visit. The latter exclusion cri-
teria leading to research plans that we called ‘only user
design’,36 have been described as reducing the poten-
tial for confounding by indication.37 We suspect that,
due to the nature of the precautions taken, confound-
ing could have biased the effect of regular service
attendance, rather than that of antipsychotic medica-
ments. Our sensitivity analysis accounting for unmeas-
ured confounding, however, showed that considering
severity of schizophrenia as the unmeasured factor,
even assuming very high prevalence of severe schizo-
phrenia at presentation (50%), and that severe schizo-
phrenics risk the outcome onset up to 10-fold more
than others, a strong discrepancy in regularity of
service attendance between severe and less severe schi-
zophrenics would be needed for making the association
of interest statistically signiﬁcant.
Figure 3 Influence of criteria for
identifying patients in regular
attendance of the Mental Health
Service and on psychotherapy on
the HR for hospital admission for
mental disorders. Lombardy
Region, Italy, 2005–2012. Criteria
concerning the time span within
which two consecutive visits for
allowing regular attendance (in
box A, patients with regular
attendance are contrasted with
those who experience at least a
discontinuing episode), and the
cumulative number of
psychotherapy sessions (in box
B, patients with at least a given
number of sessions are
contrasted with those who
experience fewer sessions).
HR estimated according to Cox
proportional hazard model.
Estimates are adjusted for
covariates listed in tables 1
and 2.
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Finally, although the sample size was large, our study
was not sufﬁciently powered to investigate the effect of
relatively rare exposures. For example, if we accept a
permissive deﬁnition of regularity (eg, by requiring at
least one contact every 3 months) then our study is
able to generate signiﬁcant evidence, admitted that
discontinuers experience the outcome at least 1.8-fold
more than regulars (with an error of the ﬁrst type of 5%
and a power of 80%). On the other hand, we do not
expect protection from such a permissive criterion. As
the deﬁnition of regularity becomes less permissive,
however, the observed number of regulars tends to
decrease. For example, our study is able to generate sig-
niﬁcant evidence of outcome protection from monthly
attendance, admitted that discontinuers experience the
outcome at least ﬁvefold more than regulars. This means
that our study has limited chance of highlighting the
impact of the proper use of the service, for the simple
reason that proper use rarely occurs. Paradoxically, this
source of weakness is due to the key message of our study,
that is, the limited use of territorial service.
In conclusion, our data on care patterns provided to
patients suffering from schizophrenic disorders in the
real-world setting, show poor adherence with anti-
psychotic drug therapy, as well as with regular attend-
ance of MHS. In addition, our study showed that good
coverage with antipsychotic therapy within the ﬁrst year
after the diagnosis of schizophrenia reduces the long-
term risk of hospital admission for mental disorders.
Real-world psychosocial treatments, such as those pro-
vided at community level by MHS in Lombardy in the
last decade, should be strengthened to be effective. The
development in Lombardy in the last 4 years of more
than 20 projects for the early treatment of psychosis is
moving in this direction. It is thus important that mental
health professionals and decision makers increase their
contribution towards improving mental healthcare in
clinical practice.
Figure 4 Modelled influence of a hypothetical confounder on
the HR for hospital admission for mental disorders
unaccounted for in the adjustments already performed in the
main analysis. Lombardy Region, Italy, 2005–2012. The graph
indicates what combinations of confounder-outcome and
confounder-exposure would be required to make significantly
protective the observed association between regular
attendance of Mental Health Service and hospitalisation for
mental disorders. For an explanation, see the ‘Sensitivity
analysis’ in the subsection of the ‘Methods’ section.
Table 2 Mental healthcare provided to the 556 included patients with diagnosis of schizophrenia and its relationship with the
long-term risk of hospital admission for mental disorders (Lombardy Region, Italy, 2005–2012)
N (%)
Rough HR*
(95% CI)
Adjusted HR*
(95% CI)
Coverage with antipsychotic drug therapy (months)†
1–4 303 (55) 1.00 (reference) 1.00 (reference)
5–8 135 (24) 0.99 (0.67 to 1.45) 0.94 (0.64 to 1.40)
9–12 118 (21) 0.71 (0.51 to 0.99) 0.69 (0.48 to 0.98)
ptrend‡ 0.052 0.043
Attendance of Mental Health Service§, ¶
Discontinue 417 (75) 1.00 (reference) 1.00 (reference)
Regular 139 (25) 1.07 (0.74 to 1.55) 0.98 (0.63 to 1.51)
Treatments§
Patient psychotherapy 124 (22) 1.08 (0.73 to 1.59) 1.02 (0.66 to 1.56)
Family psychoeducation 319 (57) 1.18 (0.84 to 1.65) 1.08 (0.76 to 1.55)
Other supports 103 (18) 1.42 (0.97 to 2.10) 1.35 (0.87 to 2.10)
Caregivers§
Only mental health professionals 44 (8) 1.00 (reference) 1.00 (reference)
Also other professionals 512 (92) 1.41 (0.74 to 2.69) 1.27 (0.65 to 2.47)
Estimates were rough and mutually adjusted for covariates listed in tables 1 and 2.
*HR (and 95% CI) for the risk of hospital admission for mental disorders, according to Cox proportional hazard model.
†Months with antipsychotic drugs available during the first year after index visit.
‡p Value for the trend in the risk of outcome as the category of the corresponding variable increases.
§During the first year after index visit.
¶Attendance was considered regular if the time span between two consecutive visits was 60 days or shorter, or discontinued, otherwise.
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